Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate or ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.
The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30
In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customers, and their patients.
Click here to learn more about our measures to help keep you and your patients safe.
The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.
*after insurance and financial assistance. $95 is the average out-of-pocket cost for patients with any cost sharing responsibility.
Subscribe for More Info
We will keep you updated with product enhancements and new product information to help you provide the best possible care for your patients
Myriad is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you: